BioAge Labs (NASDAQ:BIOA) Stock Gets Downgrade from Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other research analysts also recently weighed in on the company. Weiss Ratings downgraded BioAge Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a research note on Friday, July 31st. Roth Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of BioAge Labs in a research note on Wednesday, September 9th. BTIG Research reiterated a “buy” rating and issued a $40.00 price objective on shares of BioAge Labs in a report on Tuesday, September 8th. Finally, Needham & Company LLC cut their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BioAge Labs has a consensus rating of “Moderate Buy” and an average price target of $33.00.

BioAge Labs Price Performance

Shares of NASDAQ BIOA opened at $6.34 on Friday. BioAge Labs has a fifty-two week low of $5.04 and a fifty-two week high of $25.95. The firm has a market capitalization of $290.99 million, a P/E ratio of -2.66 and a beta of 1.08. The company’s 50 day simple moving average is $8.96 and its 200 day simple moving average is $15.54.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.07. The firm had revenue of $2.45 million during the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. Sell-side analysts expect that BioAge Labs will post -2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Engineers Gate Manager LP acquired a new stake in BioAge Labs in the second quarter worth $344,000. Squarepoint Ops LLC grew its holdings in shares of BioAge Labs by 23.3% in the 2nd quarter. Squarepoint Ops LLC now owns 68,436 shares of the company’s stock valued at $1,677,000 after buying an additional 12,916 shares during the period. Corient Private Wealth LP grew its holdings in shares of BioAge Labs by 76.7% in the 2nd quarter. Corient Private Wealth LP now owns 40,258 shares of the company’s stock valued at $987,000 after buying an additional 17,476 shares during the period. Yiheng Capital Management L.P. bought a new stake in shares of BioAge Labs in the 2nd quarter valued at $4,180,000. Finally, Wellington Management Group LLP increased its position in shares of BioAge Labs by 39.9% in the 2nd quarter. Wellington Management Group LLP now owns 94,656 shares of the company’s stock valued at $2,320,000 after buying an additional 26,975 shares in the last quarter.

BioAge Labs Company Profile

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge’s pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.